Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/0626925f-2978-45fc-9494-16d48c76261f/

SOLV

Solventum Corp.
Chart
85.44 USD
Latest Week 2026-07-31
HealthcareMedical Instruments & SuppliesLARGE
Snapshot 2026-07-26 · 1.0w · Fresh
0.78
OS Score
73.0%
Value
75.0%
Quality
30.0%
Momentum
6/9
F-Score
0.740
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
3 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
QV 0.740
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
P/E 9.4
◇
VC2 Cheapest
✗
📐
EBITDA/EV
15.3%
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
✗
🌱
GARP
✗
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
73.0%ile
P/E
9.4×
P/S
1.6×
P/B
2.7×
E/P
0.1107
FCF Yield
0.028
EBITDA/EV
0.153
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
32.00000000
/100 — 1=cheapest
VC2 (Trending Value)
68.00000000
/100
VC3 (Buyback)
23.00000000
/100
P/E of 9.4x places this firmly in deep value territory.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
75.0%ile
ROE
0.288
ROA
0.102
Net Margin
0.173
Op Margin
0.242
GPA
0.315
D/E
1.84
Current
1.07
F-Score
6/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
-0.006
Earn Growth
2.778
Stability
1.865
lower=better
Accruals
0.091
lower=better
5yr Consist
No
ROE of 29% is exceptional. Accruals ratio of 0.091 is elevated — earnings quality may be lower than headline numbers suggest.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
30.0%ile
6M Return
-1.1%
12M Return
4.4%
12-1 Mom
6.4%
Risk-Adj
0.21
Vol 252d
30.3%
Vol 60d
73.5%
↑ Expanding
Max DD 12M
-27.1%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
Near-term vol (73%) is expanding vs long-term (30%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.78
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
85.0%
Sector Quality %ile
82.4%
P/E z-score
-0.31
P/B z-score
-0.18
Sector Avg OS
64.9%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
RIGL Rigel Pharmaceuticals Inc 99.0% 92.0% 93.0% 92.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 84.0% 97.0%
FBIO Fortress Biotech Inc 99.0% 98.0% 84.0% 87.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 92.0% 90.0% 98.0%
NUTX Nutex Health Inc 99.0% 93.0% 98.0% 87.0%
CGEN Compugen 98.0% 90.0% 96.0% 83.0%
TBPH Theravance Biopharma Inc 98.0% 90.0% 99.0% 86.0%
THC Tenet Healthcare Corporation 97.0% 90.0% 91.0% 81.0%
Factor Interactions
Value + Quality Intersection
Top-tier on both cheapness (73th) and quality (75th) — the O'Shaughnessy sweet spot, historically the strongest long-term combination.
Earnings Quality Concern
ROE looks strong (29%) but high accruals (0.091) suggests earnings are accrual-heavy, not cash-backed.
Volatility Expanding
60-day vol (73%) significantly exceeds 252-day (30%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
B
63.9% avg (7 factors)
Quality
C
56.8% avg (8 factors)
Momentum
D
36.6% avg (4 factors)
Risk
B
66.2% avg (1 factors)
Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends8 snapshots
Factor Persistence8 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.780—8—
Value %ile0.730—8—
Quality %ile0.750—8—
Momentum %ile0.300—1—
F-Score6.000—0—
Confidence0.900—8—
Volatility0.303—0—
Value Lens2021-07-27 → 2026-07-26
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
9.43
Earnings Yield (E/P)
0.1107
Price / Sales
1.64
Price / Book
2.72
Price / Cash Flow
89.47
FCF Yield
2.8%
EBITDA / EV
15.3%
Sales Yield (1/P·S)
0.4583
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
28.8%
Return on Assets
10.2%
Net Margin
17.3%
Operating Margin
24.2%
Gross Profit / Assets
Novy-Marx GPA
31.5%
Debt / Equity
1.84
Current Ratio
1.07
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.091
MomentumPrice trend strength over different horizons
6M Return
-1.1%
12M Return
4.4%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
6.4%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.21
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
-0.6%
Earnings Growth (YoY)
277.8%
Earnings Stability (CV)
Lower = more stable
1.865
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
6
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
32
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
68
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
23
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity